
## **Cedric Dos Santos**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10724859/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. Transplantation and Cellular Therapy, 2021, 27, 153-162.	1.2	16
2	A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. International Journal of Hematology, 2020, 112, 223-233.	1.6	8
3	Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia. Cancer Science, 2020, 111, 1314-1323.	3.9	19
4	Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells. Haematologica, 2018, 103, 959-971.	3.5	36
5	Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene, 2018, 37, 5269-5280.	5.9	65
6	Treatment of Acute Myeloid Leukemia in Elderly Patients—AÂTherapeutic Dilemma. Journal of the American Medical Directors Association, 2016, 17, 581-587.	2.5	10
7	Signal Transduction Inhibitors as Promising Anticancer Agents. BioMed Research International, 2015, 2015, 1-2.	1.9	2
8	Combination of Dasatinib with Conventional Chemotherapy Is Associated with a High Response Rate in High Risk Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3743-3743.	1.4	3
9	SIRT1 Activation by a c-MYC Oncogenic Network Promotes the Maintenance and Drug Resistance of Human FLT3-ITD Acute Myeloid Leukemia Stem Cells. Cell Stem Cell, 2014, 15, 431-446.	11.1	187
10	The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. Blood, 2013, 122, 1900-1913.	1.4	86
11	In Vivo Targeting Of Acute Myeloid Leukemia Using CpG-Stat3 siRNA Results In T Cell-Dependent Tumor Eradication. Blood, 2013, 122, 4212-4212.	1.4	1
12	A functional link between Polo-like kinase 1 and the mammalian Target-Of-Rapamycin pathway?. Cell Cycle, 2010, 9, 1690-1696.	2.6	26
13	Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood, 2009, 114, 659-662.	1.4	127
14	A critical role for Lyn in acute myeloid leukemia. Blood, 2008, 111, 2269-2279.	1.4	137
15	Antileukemic activity of rapamycin in acute myeloid leukemia. Blood, 2005, 105, 2527-2534.	1.4	280
16	mTOR, A New Therapeutic Target in Acute Myeloid Leukemia. Cell Cycle, 2005, 4, 1540-1549.	2.6	90